Enhanced Liver Fibrosis® Test Predicts Liver-related Outcomes in the General Population

Overview

Journal JHEP Rep

Specialty Gastroenterology

Date 2023 Jun 19

PMID 37333973

Authors

Kustaa Saarinen

Martti Farkkila

Antti Jula

Iris Erlund

Terhi Vihervaara

Annamari Lundqvist

Fredrik Aberg

Affiliations

Soon will be listed here.

Abstract

Background & Aims: The Enhanced Liver Fibrosis® (ELF) test exhibits good discriminative performance in detecting advanced liver fibrosis and in predicting liver-related outcomes in patients with specific liver diseases, but large population-based studies are missing. We analysed the predictive performance of the ELF test in a general population cohort.

Methods: Data were sourced from the Health 2000 study, a Finnish population-based health examination survey conducted in 2000-2001. Subjects with baseline liver disease were excluded. The ELF test was performed on blood samples collected at baseline. Data were linked with national healthcare registers for liver-related outcomes (hospitalisation, cancer, and death).

Results: The cohort comprised 6,040 individuals (mean age 52.7. 45.6% men) with 67 liver-related outcomes during a median 13.1-year follow-up. ELF predicted liver outcomes (unadjusted hazards ratio 2.70, 95% CI 2.16-3.38). with 5- and 10-year AUCs of 0.81 (95% CI 0.71-0.91) and 0.71 (95% CI 0.63-0.79) by competing-risk methodology. The 10-year risks for liver outcomes increased from 0.5% at ELF <9.8 to 7.1% at ELF ≥11.3, being higher among men than women at any given ELF level. Among individuals with body mass index ≥30 kg/m, diabetes, or alanine aminotransferase >40 U/L. Five-year AUCs for ELF were 0.85, 0.87, and 0.88, respectively. The predictive ability of the ELF test decreased with time: the 10-year AUCs were 0.78, 0.69, and 0.82, respectively.

Conclusions: The ELF test shows good discriminative performance in predicting liver-related outcomes in a large general population cohort and appears particularly useful for predicting 5-year outcomes in persons with risk factors.

Impact And Implications: The Enhanced Liver Fibrosis test exhibits good performance for predicting liver-related outcomes (hospitalisation, liver cancer, or liver-related death) in the general population, especially in those with risk factors.

Citing Articles

Metabolic dysfunction-associated steatotic liver disease in adults.

Huang D, Wong V, Rinella M, Boursier J, Lazarus J, Yki-Jarvinen H Nat Rev Dis Primers. 2025; 11(1):14.

PMID: 40050362 DOI: 10.1038/s41572-025-00599-1.

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025.

Diabetes Care. 2024; 48(Supplement_1):S59-S85.

PMID: 39651988 PMC: 11635044. DOI: 10.2337/dc25-S004.

Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Kang Y, Baek Y, Moon S Diagnostics (Basel). 2024; 14(22).

PMID: 39594183 PMC: 11592410. DOI: 10.3390/diagnostics14222517.

Population screening for cirrhosis.

Thiele M, Pose E, Juanola A, Mellinger J, Gines P Hepatol Commun. 2024; 8(9).

PMID: 39185917 PMC: 11357699. DOI: 10.1097/HC9.0000000000000512.

Enhanced liver fibrosis (ELF) score predicts hepatic decompensation and mortality.

Pearson M, Nobes J, MacPherson I, Gold L, Miller M, Dow E JHEP Rep. 2024; 6(6):101062.

PMID: 38826498 PMC: 11141136. DOI: 10.1016/j.jhepr.2024.101062.

References

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2020; 44(Suppl 1):S15-S33. DOI: 10.2337/dc21-S002. View

Hagstrom H, Talback M, Andreasson A, Walldius G, Hammar N . Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease. Gastroenterology. 2019; 158(1):200-214. DOI: 10.1053/j.gastro.2019.09.008. View

Guha I, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S . Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2007; 47(2):455-60. DOI: 10.1002/hep.21984. View

Kennedy O, Parkes J, Tanwar S, Trembling P, Rosenberg W . The Enhanced Liver Fibrosis (ELF) Panel: Analyte Stability Under Common Sample Storage Conditions Used in Clinical Practice. J Appl Lab Med. 2020; 1(6):720-728. DOI: 10.1373/jalm.2016.022806. View

Blanche P, Kattan M, Gerds T . The c-index is not proper for the evaluation of $t$-year predicted risks. Biostatistics. 2018; 20(2):347-357. DOI: 10.1093/biostatistics/kxy006. View

Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H . Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology. 2015; 150(3):626-637.e7. DOI: 10.1053/j.gastro.2015.11.048. View

Irvine K, Wockner L, Shanker M, Fagan K, Horsfall L, Fletcher L . The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver Int. 2015; 36(3):370-7. DOI: 10.1111/liv.12896. View

Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R . Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017; 67(6):1265-1273. DOI: 10.1016/j.jhep.2017.07.027. View

10.

Lichtinghagen R, Pietsch D, Bantel H, Manns M, Brand K, Bahr M . The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol. 2013; 59(2):236-42. DOI: 10.1016/j.jhep.2013.03.016. View

11.

Mayo M, Parkes J, Adams-Huet B, Combes B, Mills A, Markin R . Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology. 2008; 48(5):1549-57. PMC: 2597274. DOI: 10.1002/hep.22517. View

12.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

13.

Younossi Z, Tacke F, Arrese M, Sharma B, Mostafa I, Bugianesi E . Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2018; 69(6):2672-2682. DOI: 10.1002/hep.30251. View

14.

Puigvehi M, Hernandez J, Broquetas T, Coll S, Garcia-Retortillo M, Canete N . Diagnostic Accuracy of the Enhanced Liver Fibrosis (ELF®) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 Years. PLoS One. 2016; 11(12):e0164883. PMC: 5161309. DOI: 10.1371/journal.pone.0164883. View

15.

Dulai P, Singh S, Patel J, Soni M, Prokop L, Younossi Z . Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017; 65(5):1557-1565. PMC: 5397356. DOI: 10.1002/hep.29085. View

16.

Vesterhus M, Hov J, Holm A, Schrumpf E, Nygard S, Godang K . Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology. 2015; 62(1):188-97. DOI: 10.1002/hep.27825. View

17.

Are V, Vuppalanchi R, Vilar-Gomez E, Chalasani N . Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis. Clin Gastroenterol Hepatol. 2020; 19(6):1292-1293.e3. DOI: 10.1016/j.cgh.2020.06.070. View

18.

De Vincentis A, Tavaglione F, Jamialahmadi O, Picardi A, Antonelli Incalzi R, Valenti L . A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores. Clin Gastroenterol Hepatol. 2021; 20(3):658-673. DOI: 10.1016/j.cgh.2021.05.056. View

19.

Rahman M, Ambler G, Choodari-Oskooei B, Omar R . Review and evaluation of performance measures for survival prediction models in external validation settings. BMC Med Res Methodol. 2017; 17(1):60. PMC: 5395888. DOI: 10.1186/s12874-017-0336-2. View

20.

Fujinaga Y, Namisaki T, Takaya H, Tsuji Y, Suzuki J, Shibamoto A . Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis. Medicine (Baltimore). 2021; 100(39):e27403. PMC: 8483841. DOI: 10.1097/MD.0000000000027403. View